;PMID: 7980623
;source_file_935.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..228] = [t:51..228]
;2)section:[e:232..298] = [t:232..298]
;3)section:[e:302..380] = [t:302..380]
;4)sentence:[e:384..733] = [t:384..733]
;5)sentence:[e:734..879] = [t:734..879]
;6)sentence:[e:880..990] = [t:880..990]
;7)sentence:[e:991..1121] = [t:991..1121]
;8)sentence:[e:1123..1234] = [t:1123..1234]
;9)sentence:[e:1235..1381] = [t:1235..1381]
;10)sentence:[e:1382..1598] = [t:1382..1598]
;11)sentence:[e:1599..1783] = [t:1599..1783]
;12)section:[e:1787..1831] = [t:1787..1831]

;section 0 Span:0..45
;Biochem Pharmacol. 1994 Oct 18;48(8):1577-82.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1994) (NNP:[24..27] Oct) (CC:[28..34] 18;48-LRB-)
        (CD:[34..35] 8) (-RRB-:[35..36] -RRB-) (CD:[36..41] :1577)
        (::[41..42] -) (CD:[42..44] 82) (.:[44..45] .)))

;sentence 1 Span:51..228
;Selectivity of isoprenoid-containing imidazole antifungal compounds for
;sterol  14-demethylase P450 (P450(14)DM) and 7-ethoxycoumarin O-deethylase
;P450 of rat  liver microsomes.
;[66..76]:substance:"isoprenoid"
;[88..118]:substance:"imidazole antifungal compounds"
;[123..150]:cyp450:"sterol  14-demethylase P450"
;[152..162]:cyp450:"P450(14)DM"
;[168..202]:cyp450:"7-ethoxycoumarin O-deethylase P450"
(SENT
  (NP-HLN
    (NP (NN:[51..62] Selectivity))
    (PP (IN:[63..65] of)
      (NP
        (NP
          (ADJP (NN:[66..76] isoprenoid) (HYPH:[76..77] -)
                (VBG:[77..87] containing))
           (NN:[88..97] imidazole) (JJ:[98..108] antifungal)
           (NNS:[109..118] compounds))
        (PP (IN:[119..122] for)
          (NP
            (NP
              (NP
                (NP (NN:[123..129] sterol) (NN:[131..145] 14-demethylase)
                    (NN:[146..150] P450))
                (NP (-LRB-:[151..152] -LRB-) (NN:[152..162] P450-LRB-14-RRB-DM)
                    (-RRB-:[162..163] -RRB-)))
              (CC:[164..167] and)
              (NP (NN:[168..184] 7-ethoxycoumarin) (NN:[185..197] O-deethylase)
                  (NN:[198..202] P450)))
            (PP (IN:[203..205] of)
              (NP (NN:[206..209] rat) (NN:[211..216] liver)
                  (NNS:[217..227] microsomes)))))))
    (.:[227..228] .)))

;section 2 Span:232..298
;Ito T, Aoyama Y, Ishida K, Kudoh M, Hori K, Tsuchiya S, Yoshida Y.
(SEC
  (FRAG (NNP:[232..235] Ito) (NNP:[236..237] T) (,:[237..238] ,)
        (NNP:[239..245] Aoyama) (NNP:[246..247] Y) (,:[247..248] ,)
        (NNP:[249..255] Ishida) (NNP:[256..257] K) (,:[257..258] ,)
        (NNP:[259..264] Kudoh) (NNP:[265..267] M,) (NNP:[268..272] Hori)
        (NNP:[273..274] K) (,:[274..275] ,) (NNP:[276..284] Tsuchiya)
        (NNP:[285..287] S,) (NNP:[288..295] Yoshida) (NNP:[296..298] Y.)))

;section 3 Span:302..380
;Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Hyogo,
;Japan.
(SEC
  (FRAG (IN:[302..309] Faculty) (IN:[310..312] of)
        (NNP:[313..327] Pharmaceutical) (NNPS:[328..336] Sciences)
        (,:[336..337] ,) (NNP:[338..346] Mukogawa) (NNP:[347..352] Women)
        (POS:[352..354] 's) (NNP:[355..365] University) (,:[365..366] ,)
        (NNP:[367..372] Hyogo) (,:[372..373] ,) (NNP:[374..379] Japan)
        (.:[379..380] .)))

;sentence 4 Span:384..733
;The imidazole antifungal compound AFK-108 
;(1-[2-(2,4-dichlorophenyl)-2-((2E)-3,7-dimethylocta-2,6- 
;dienyloxy)ethyl]-1H-imidazole) has been shown to be a potent inhibitor for
;yeast  lanosterol 14 alpha-demethylase (P450(14)DM), interacting specifically
;with the  sterol side-chain recognition part of the substrate site through
;its geranyl  moiety.
;[388..417]:substance:"imidazole antifungal compound"
;[418..425]:substance:"AFK-108"
;[428..514]:substance:"1-[2-(2,4-dichlorophenyl)-2-((2E)-3,7-dimethylocta-2,6-
; dienyloxy)ethyl]-1H-imidazole"
;[546..555]:substance:"inhibitor"
;[567..598]:cyp450:"lanosterol 14 alpha-demethylase"
;[600..610]:cyp450:"P450(14)DM"
;[648..654]:substance:"sterol"
;[690..699]:substance:"substrate"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[384..387] The)
         (NN:[388..397] imidazole) (JJ:[398..408] antifungal)
         (NN:[409..417] compound))
      (NP
        (NP (NN:[418..425] AFK-108))
        (NP (-LRB-:[427..428] -LRB-)
          
           (NN:[428..482] 1--LSB-2--LRB-2,4-dichlorophenyl-RRB--2--LRB--LRB-2E-RRB--3,7-dimethylocta-2,6)
           (HYPH:[482..483] -)
           (NN:[485..514] dienyloxy-RRB-ethyl-RSB--1H-imidazole)
          (-RRB-:[514..515] -RRB-))))
    (VP (VBZ:[516..519] has)
      (VP (VBN:[520..524] been)
        (VP (VBN:[525..530] shown)
          (S
            (NP-SBJ-1 (-NONE-:[530..530] *))
            (VP (TO:[531..533] to)
              (VP (VB:[534..536] be)
                (NP-PRD
                  (NP (DT:[537..538] a) (JJ:[539..545] potent)
                      (NN:[546..555] inhibitor))
                  (PP (IN:[556..559] for)
                    (NP
                      (NP (NN:[560..565] yeast)
                         (NN:[567..577] lanosterol) (CD:[578..580] 14)
                         (NN:[581..598] alpha-demethylase))
                      (NP (-LRB-:[599..600] -LRB-)
                          (NN:[600..610] P450-LRB-14-RRB-DM)
                          (-RRB-:[610..611] -RRB-)))))
                (,:[611..612] ,)
                (S-ADV
                  (NP-SBJ-1 (-NONE-:[612..612] *))
                  (VP (VBG:[613..624] interacting)
                    (ADVP (RB:[625..637] specifically))
                    (PP (IN:[638..642] with)
                      (NP
                        (NP (DT:[643..646] the)
                          (NML (NN:[648..654] sterol)
                            (NML (NN:[655..659] side) (HYPH:[659..660] -)
                                 (NN:[660..665] chain))
                            (NN:[666..677] recognition))
                          (NN:[678..682] part))
                        (PP (IN:[683..685] of)
                          (NP (DT:[686..689] the) (NN:[690..699] substrate)
                              (NN:[700..704] site)))))
                    (PP-MNR (IN:[705..712] through)
                      (NP (PRP$:[713..716] its) (NN:[717..724] geranyl)
                          (NN:[726..732] moiety)))))))))))
    (.:[732..733] .)))

;sentence 5 Span:734..879
;AFK-108 acted as a potent inhibitor for rat liver P450(14)DM, while its 
;farnesyl (AFK-110) and prenyl (AFK-122) homologues were weak inhibitors.
;[734..741]:substance:"AFK-108"
;[760..769]:substance:"inhibitor"
;[784..794]:cyp450:"P450(14)DM"
;[807..815]...[847..857]:substance:"farnesyl"..."homologues"
;[817..824]:substance:"AFK-110"
;[830..836]...[847..857]:substance:"prenyl"..."homologues"
;[838..845]:substance:"AFK-122"
;[868..878]:substance:"inhibitors"
(SENT
  (S
    (NP-SBJ (NN:[734..741] AFK-108))
    (VP (VBD:[742..747] acted)
      (PP-CLR (IN:[748..750] as)
        (NP
          (NP (DT:[751..752] a) (JJ:[753..759] potent) (NN:[760..769] inhibitor))
          (PP (IN:[770..773] for)
            (NP (NN:[774..777] rat) (NN:[778..783] liver)
                (NN:[784..794] P450-LRB-14-RRB-DM)))))
      (,:[794..795] ,)
      (SBAR-ADV (IN:[796..801] while)
        (S
          (NP-SBJ (PRP$:[802..805] its)
            (NML
              (NML
                (NML
                  (NML (NN:[807..815] farnesyl))
                  (NML (-LRB-:[816..817] -LRB-) (NN:[817..824] AFK-110)
                       (-RRB-:[824..825] -RRB-)))
                (NML-1 (-NONE-:[825..825] *P*)))
              (CC:[826..829] and)
              (NML
                (NML
                  (NML (NN:[830..836] prenyl))
                  (NML (-LRB-:[837..838] -LRB-) (NN:[838..845] AFK-122)
                       (-RRB-:[845..846] -RRB-)))
                (NML-1 (NNS:[847..857] homologues)))))
          (VP (VBD:[858..862] were)
            (NP-PRD (JJ:[863..867] weak) (NNS:[868..878] inhibitors))))))
    (.:[878..879] .)))

;sentence 6 Span:880..990
;This  indicates that AFK-108 interacts with rat liver P450(14(DM in the same
;manner as  with the yeast enzyme.
;[901..908]:substance:"AFK-108"
;[934..944]:cyp450:"P450(14(DM"
;[983..989]:cyp450:"enzyme"
(SENT
  (S
    (NP-SBJ (DT:[880..884] This))
    (VP (VBZ:[886..895] indicates)
      (SBAR (IN:[896..900] that)
        (S
          (NP-SBJ (NN:[901..908] AFK-108))
          (VP (VBZ:[909..918] interacts)
            (PP-CLR (IN:[919..923] with)
              (NP (NN:[924..927] rat) (NN:[928..933] liver)
                  (NN:[934..944] P450-LRB-14-LRB-DM)))
            (PP-MNR (IN:[945..947] in)
              (NP
                (NP (DT:[948..951] the) (JJ:[952..956] same)
                    (NN:[957..963] manner))
                (PP (IN:[964..966] as)
                  (PP (IN:[968..972] with)
                    (NP (DT:[973..976] the) (NN:[977..982] yeast)
                        (NN:[983..989] enzyme))))))))))
    (.:[989..990] .)))

;sentence 7 Span:991..1121
;However, the difference between the potency of AFK-108  and the homologues
;was greater in rat P450(14)DM than in the yeast enzyme.
;[1038..1045]:substance:"AFK-108"
;[1055..1065]:substance:"homologues"
;[1085..1095]:cyp450:"P450(14)DM"
;[1114..1120]:cyp450:"enzyme"
(SENT
  (S
    (ADVP (RB:[991..998] However))
    (,:[998..999] ,)
    (NP-SBJ
      (NP (DT:[1000..1003] the) (NN:[1004..1014] difference))
      (PP (IN:[1015..1022] between)
        (NP
          (NP (DT:[1023..1026] the) (NN:[1027..1034] potency))
          (PP (IN:[1035..1037] of)
            (NP
              (NP (NN:[1038..1045] AFK-108))
              (CC:[1047..1050] and)
              (NP (DT:[1051..1054] the) (NNS:[1055..1065] homologues)))))))
    (VP (VBD:[1066..1069] was)
      (ADJP-PRD
        (ADJP (JJR:[1070..1077] greater))
        (PP-1 (-NONE-:[1077..1077] *ICH*)))
      (PP-LOC (IN:[1078..1080] in)
        (NP (NN:[1081..1084] rat) (NN:[1085..1095] P450-LRB-14-RRB-DM)))
      (PP-1 (IN:[1096..1100] than)
        (PP-LOC (IN:[1101..1103] in)
          (NP (DT:[1104..1107] the) (NN:[1108..1113] yeast)
              (NN:[1114..1120] enzyme)))))
    (.:[1120..1121] .)))

;sentence 8 Span:1123..1234
;AFK-108 and its homologues partially inhibited 7-ethoxycoumarin O-deethylase 
;activity of rat liver microsomes.
;[1123..1130]:substance:"AFK-108"
;[1139..1149]:substance:"homologues"
;[1170..1199]:substance:"7-ethoxycoumarin O-deethylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1123..1130] AFK-108))
      (CC:[1131..1134] and)
      (NP (PRP$:[1135..1138] its) (NNS:[1139..1149] homologues)))
    (ADVP-EXT (RB:[1150..1159] partially))
    (VP (VBD:[1160..1169] inhibited)
      (NP
        (NP
          (NML (NN:[1170..1186] 7-ethoxycoumarin) (NN:[1187..1199] O-deethylase))
          (NN:[1201..1209] activity))
        (PP (IN:[1210..1212] of)
          (NP (NN:[1213..1216] rat) (NN:[1217..1222] liver)
              (NNS:[1223..1233] microsomes)))))
    (.:[1233..1234] .)))

;sentence 9 Span:1235..1381
;The order of potency was AFK-122 > AFK-108 >  AFK-110, indicating that some
;steric hindrance of the isoprenoid moiety might  affect their potency.
;[1260..1267]:substance:"AFK-122"
;[1270..1277]:substance:"AFK-108"
;[1281..1288]:substance:"AFK-110"
;[1335..1345]:substance:"isoprenoid"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1235..1238] The) (NN:[1239..1244] order))
      (PP (IN:[1245..1247] of)
        (NP (NN:[1248..1255] potency))))
    (VP (VBD:[1256..1259] was)
      (NP-PRD
        (NP (NN:[1260..1267] AFK-122))
        (PP (SYM:[1268..1269] >)
          (NP
            (NP (NN:[1270..1277] AFK-108))
            (PP (SYM:[1278..1279] >)
              (NP (NN:[1281..1288] AFK-110))))))
      (,:[1288..1289] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1289..1289] *))
        (VP (VBG:[1290..1300] indicating)
          (SBAR (IN:[1301..1305] that)
            (S
              (NP-SBJ
                (NP (DT:[1306..1310] some) (JJ:[1311..1317] steric)
                    (NN:[1318..1327] hindrance))
                (PP (IN:[1328..1330] of)
                  (NP (DT:[1331..1334] the) (JJ:[1335..1345] isoprenoid)
                      (NN:[1346..1352] moiety))))
              (VP (MD:[1353..1358] might)
                (VP (VB:[1360..1366] affect)
                  (NP (PRP$:[1367..1372] their) (NN:[1373..1380] potency)))))))))
    (.:[1380..1381] .)))

;sentence 10 Span:1382..1598
;The inhibitory effect of AFK-108 for P450(14)DM was  considerably higher than
;for 7-ethoxycoumarin O-deethylase P450, while the  inhibition of AFK-110 and
;AFK-122 on these enzymes was of the same order of  magnitude.
;[1407..1414]:substance:"AFK-108"
;[1419..1429]:cyp450:"P450(14)DM"
;[1464..1498]:cyp450:"7-ethoxycoumarin O-deethylase P450"
;[1525..1532]:substance:"AFK-110"
;[1537..1544]:substance:"AFK-122"
;[1554..1561]:cyp450:"enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1382..1385] The) (JJ:[1386..1396] inhibitory)
          (NN:[1397..1403] effect))
      (PP (IN:[1404..1406] of)
        (NP (NN:[1407..1414] AFK-108)))
      (PP (IN:[1415..1418] for)
        (NP (NN:[1419..1429] P450-LRB-14-RRB-DM))))
    (VP (VBD:[1430..1433] was)
      (ADJP-PRD
        (ADJP (RB:[1435..1447] considerably) (JJR:[1448..1454] higher))
        (PP (IN:[1455..1459] than)
          (PP (IN:[1460..1463] for)
            (NP (NN:[1464..1480] 7-ethoxycoumarin)
                (NN:[1481..1493] O-deethylase) (NN:[1494..1498] P450)))))
      (,:[1498..1499] ,)
      (SBAR-ADV (IN:[1500..1505] while)
        (S
          (NP-SBJ
            (NP (DT:[1506..1509] the) (NN:[1511..1521] inhibition))
            (PP (IN:[1522..1524] of)
              (NP
                (NP (NN:[1525..1532] AFK-110) (CC:[1533..1536] and)
                    (NN:[1537..1544] AFK-122))
                (PP (IN:[1545..1547] on)
                  (NP (DT:[1548..1553] these) (NNS:[1554..1561] enzymes))))))
          (VP (VBD:[1562..1565] was)
            (PP-PRD (IN:[1566..1568] of)
              (NP
                (NP (DT:[1569..1572] the) (JJ:[1573..1577] same)
                    (NN:[1578..1583] order))
                (PP (IN:[1584..1586] of)
                  (NP (NN:[1588..1597] magnitude)))))))))
    (.:[1597..1598] .)))

;sentence 11 Span:1599..1783
;These results suggest that azole compounds interacting with the  side-chain
;recognition site of P450(14)DM may be good candidates as antifungal  agents
;selective for fungal P450(14)DM.
;[1626..1641]:substance:"azole compounds"
;[1695..1705]:cyp450:"P450(14)DM"
;[1732..1750]:substance:"antifungal  agents"
;[1772..1782]:cyp450:"P450(14)DM"
(SENT
  (S
    (NP-SBJ (DT:[1599..1604] These) (NNS:[1605..1612] results))
    (VP (VBP:[1613..1620] suggest)
      (SBAR (IN:[1621..1625] that)
        (S
          (NP-SBJ
            (NP (NN:[1626..1631] azole) (NNS:[1632..1641] compounds))
            (VP (VBG:[1642..1653] interacting)
              (PP-CLR (IN:[1654..1658] with)
                (NP
                  (NP (DT:[1659..1662] the)
                    (NML (NN:[1664..1668] side) (HYPH:[1668..1669] -)
                         (NN:[1669..1674] chain))
                    (NN:[1675..1686] recognition) (NN:[1687..1691] site))
                  (PP (IN:[1692..1694] of)
                    (NP (NN:[1695..1705] P450-LRB-14-RRB-DM)))))))
          (VP (MD:[1706..1709] may)
            (VP (VB:[1710..1712] be)
              (NP-PRD (JJ:[1713..1717] good) (NNS:[1718..1728] candidates))
              (PP (IN:[1729..1731] as)
                (NP
                  (NP (JJ:[1732..1742] antifungal) (NNS:[1744..1750] agents))
                  (ADJP (JJ:[1751..1760] selective)
                    (PP (IN:[1761..1764] for)
                      (NP (JJ:[1765..1771] fungal)
                          (NN:[1772..1782] P450-LRB-14-RRB-DM)))))))))))
    (.:[1782..1783] .)))

;section 12 Span:1787..1831
;PMID: 7980623 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1787..1791] PMID) (::[1791..1792] :) (CD:[1793..1800] 7980623)
        (NN:[1801..1802] -LSB-) (NNP:[1802..1808] PubMed) (::[1809..1810] -)
        (NN:[1811..1818] indexed) (IN:[1819..1822] for)
        (NNP:[1823..1831] MEDLINE-RSB-)))
